Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents (review).
Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents (review).
复制标题
DOI：
10.3892/ijo.21.6.1161
复制
发表时间：
2002-12
影响因子：
5.2
通讯作者：
G. Bauerschmitz;S. Barker;A. Hemminki
中科院分区：
文献类型：
--
作者：
G. Bauerschmitz;S. Barker;A. Hemminki
基因治疗是一种令人兴奋的新方法，用于治疗对目前可用的模式具有抗性的癌症。治疗方法基于利用正常细胞和肿瘤细胞之间的分子差异。各种策略目前正在临床开发中，报告了突变补偿、分子化疗和复制能力病毒的一些有希望的早期结果。腺病毒是最受欢迎的载体之一，有大量的临床数据表明其对癌症患者的治疗具有极好的安全性。目前的发展包括改进靶向策略，用于用肿瘤特异性启动子将基因递送至肿瘤细胞。另一个快速发展的领域是复制活性剂，其允许改善的肿瘤穿透和抗肿瘤作用的局部放大。此外，感染性增强策略可以克服肿瘤细胞上主要腺病毒受体的可变表达，这可能降低了先前策略的临床疗效。腺病毒癌症基因治疗方法缺乏与其他治疗选择的交叉耐药性，并且经常可以观察到协同效应。因此，第一个常规临床应用可能是联合治疗。
Gene therapy is an exciting novel approach for treating cancers resistant to currently available modalities. Treatment approaches are based on taking advantage of molecular differences between normal and tumor cells. Various strategies are currently in clinical development, with some promising early results reported with mutation compensation, molecular chemotherapy and replication competent viruses. Adenoviruses are among the most popular vehicles and there is a wealth of clinical data suggesting excellent safety for treatment of cancer patients. Current developments include improving targeting strategies for gene delivery to tumor cells with tumor specific promoters. Another rapidly developing field is replication competent agents, which allow improved tumor penetration and local amplification of the anti-tumor effect. Further, infectivity enhancement strategies can overcome variable expression of the primary adenovirus receptor on tumor cells, which may have reduced the clinical efficacy of previous strategies. Adenoviral cancer gene therapy approaches lack cross-resistance with other treatment options and frequently synergistic effects can be observed. Therefore, the first routine clinical applications are likely to be combination treatments.